Drug Profile
Zanoterone
Alternative Names: WIN 49596Latest Information Update: 06 Aug 2002
Price :
$50
*
At a glance
- Originator Eastman Kodak; Sanofi Winthrop
- Class Antiandrogens; Antineoplastics; Hormones
- Mechanism of Action Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Benign prostatic hyperplasia; Prostate cancer
Most Recent Events
- 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
- 02 Mar 1998 Phase-II clinical trials for Benign prostatic hyperplasia in USA (PO)
- 24 Feb 1998 No-Development-Reported for Benign prostatic hyperplasia in USA (PO)